3 results
Approved WMOCompleted
Primary ObjectivesTo assess the safety of 2 fixed doses of EVP-6124 (2 or 3 mg daily) for up to 52 weeks in subjects withAlzheimer*s disease (AD) who complete (Day 182) studies EVP-6124-024 or EVP-6124-025Secondary ObjectivesTo assess the duration…
Approved WMOCompleted
In the current study we want to evaluate the correlation between hepatic uptake of Rienso and the histological NAFLD activity score (NAS, necroinflammatory grade) in liver biopsy specimens from patients suspected of having NASH. Besides, we want to…
Approved WMOCompleted
In the current study, we want to demonstrate Rienso uptake in the vessel wall in patients with cardiovascular disease and relate the uptake of Rienso to endothelial permeability.